First, Shionogi has completed its $2.5 billion acquisition of global rights to the ALS treatment Radicava from Tanabe Pharma. This deal marks a strategic inflection point, shifting the company beyond its infectious disease roots into a commercially active rare disease player. The acquisition includes Radicava’s U.S. commercial infrastructure and is expected to contribute approximately $700 million in annual revenue starting in fiscal year 2026.
Next, health systems are closely monitoring the U.S.-Iran war for potential medical supply disruptions. While analysts do not currently expect major shortages—noting the Persian Gulf is not a primary source of drug manufacturing—the closure of the Strait of Hormuz is driving up costs. Increased reliance on air transport and rising prices for regional petrochemicals used in drug production are expected to impact pricing. Experts strongly advise hospitals against stocking up, warning that panic-buying could create artificial shortages where none currently exist.
That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.
